These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 14555296)
1. Evaluation of a didanosin-containing regimen including genotypic resistance testing: an open-label, multicenter study. Treichel S; Hartmann M; Rump A; Brust J; Schuster D; Mosthaf F; Procaccianti M; Klinker H; Petzoldt D Eur J Med Res; 2003 Sep; 8(9):405-13. PubMed ID: 14555296 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients. Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754 [TBL] [Abstract][Full Text] [Related]
3. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection. Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257 [TBL] [Abstract][Full Text] [Related]
4. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine. Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734 [TBL] [Abstract][Full Text] [Related]
5. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks. Paton NI; Aboulhab J HIV Med; 2005 Jan; 6(1):13-20. PubMed ID: 15670247 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients. de Mendoza C; Soriano V; Pérez-Olmeda M; Rodríguez-Rosado R; González-Lahoz J J Hum Virol; 2000; 3(6):335-40. PubMed ID: 11100914 [TBL] [Abstract][Full Text] [Related]
8. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study. Reliquet V; Allavena C; François-Brunet C; Perré P; Bellein V; Garré M; May T; Souala F; Besnier JM; Raffi F HIV Med; 2006 Oct; 7(7):431-6. PubMed ID: 16925728 [TBL] [Abstract][Full Text] [Related]
9. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V; J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728 [TBL] [Abstract][Full Text] [Related]
10. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy. Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718 [TBL] [Abstract][Full Text] [Related]
11. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study. Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096 [TBL] [Abstract][Full Text] [Related]
12. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. Bossi P; Peytavin G; Ait-Mohand H; Delaugerre C; Ktorza N; Paris L; Bonmarchand M; Cacace R; David DJ; Simon A; Lamotte C; Marcelin AG; Calvez V; Bricaire F; Costagliola D; Katlama C HIV Med; 2004 Sep; 5(5):352-9. PubMed ID: 15369510 [TBL] [Abstract][Full Text] [Related]